Direct-to-Consumer Genetic Testing Market (By Test Type: Nutrigenomics Testing, Predictive Testing, Carrier Testing, Skincare testing, Ancestry & Relationship testing; By Technology Type: Target Analysis, Single Nucleotide Polymorphism (SNP) chips, Whole Genome Sequencing (WGS); By Distribution Channel: Online Platforms, Over The Counter) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Direct-to-Consumer Genetic Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Direct-to-Consumer Genetic Testing Market, by Test Type, 2024-2033
8.1.1 Nutrigenomics Testing
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Predictive Testing
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Carrier Testing
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Skincare testing
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Ancestry & Relationship testing
8.1.5.1. Market Revenue and Forecast (2021-2033)
9.1. Direct-to-Consumer Genetic Testing Market, by Technology Type, 2024-2033
9.1.1. Target Analysis
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Single Nucleotide Polymorphism (SNP) chips
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Whole Genome Sequencing (WGS)
9.1.3.1. Market Revenue and Forecast (2021-2033)
10.1. Direct-to-Consumer Genetic Testing Market, by Distribution Channel, 2024-2033
10.1.1. Online Platforms
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Over The Counter
10.1.2.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Test Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.1. Ancestry
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Color Health, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Easy DNA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. FamilyTreeDNA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Full Genome Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Helix OpCo LLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Identigene
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Karmagenes
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Living DNA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Mapmygenome
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample